Skip to content

Neurocrine Biosciences

US · NBIX #1162 by market cap Listed 1970
150.57 -6.02 -3.84%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 157.24 +0.42%
After-hours 150.57 0.00%
Overnight 155.00 -1.02%
185.50135.13150.572026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on NBIX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +3.4% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days D → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall A+
ValuationGrowthProfitMomentumHealthAnalyst
Valuation B-

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 22.3x Better than 36%
Forward P/E 17.0x Better than 48%
Price / Sales 4.5x Better than 26%
P/E vs own 5-yr range 12th pctl Better than 90%
Growth A

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 24.3% Better than 86%
Net income CAGR (3Y) 45.8% Better than 87%
Free cash flow CAGR (3Y) 32.4% Better than 76%
Profitability A

How much profit the business keeps from each dollar of sales and capital.

Gross margin 98.2% Better than 99%
Operating margin 22.3% Better than 80%
Net margin 16.7% Better than 74%
Return on equity 16.4% Better than 71%
Return on invested capital 12.4% Better than 77%
Momentum B-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -1.3% Better than 70%
6-month return -3.9% Better than 49%
12-month return (ex latest month) 1.0% Better than 34%
Distance below 52-week high 19.1% Better than 62%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 3.4x Better than 77%
Debt to assets 9.0% Better than 72%
Interest coverage 4.8x Better than 56%
Free cash flow / net income 156.4% Better than 67%
Analyst View B+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 85.0% Better than 67%
Upside to average target 37.8% Better than 57%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -10.05%
1M +6.04%
3M -1.54%
6M -2.65%
YTD +6.16%
1Y +8.34%
3Y +37.59%
5Y +75.04%

Key statistics

Price & volume

Prev close
156.59
Open
156.27
Day range
150.24 - 158.26
Avg price
152.61
Volume
1.59M
Turnover
242.24M
Amplitude
5.12%
52-week range
122.14 - 186.12

Valuation

P/E
32.24
P/E (TTM)
22.34
P/B
3.93
EPS
4.67
Net profit
472.69M
Net assets
3.88B

Share structure

Market cap
15.24B
Float cap
15.04B
Shares out
101.22M
Float shares
99.91M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 44% of range
122.14 186.12

19.1% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-52.74M net over the window

Short interest

Shares short
5.90M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Neurocrine Biosciences (NBIX)?

Neurocrine Biosciences last traded at 150.57. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Neurocrine Biosciences's market cap?

About 15.24B.

What is the P/E ratio of Neurocrine Biosciences?

The trailing twelve-month P/E is 22.34, below its own 5-year average of 98.52 — toward the bottom of its historical range (7.65% percentile). See the Valuation tab for the full history.

Does Neurocrine Biosciences pay a dividend?

Neurocrine Biosciences does not currently pay a regular dividend.

Is Neurocrine Biosciences a buy according to analysts?

The consensus of 19 analysts is a Buy rating, with an average 12-month price target of 207.35, which implies 37.7% upside from the current price. This is not investment advice.

What is Neurocrine Biosciences's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Neurocrine Biosciences a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Neurocrine Biosciences discussion 0 comments

Add a comment